WA
XBI icon

Winfield Associates’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Winfield Associates’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$1.09M Sell
12,117
-33,471
-73% -$3.09M 0.39% 63
2021
Q4 		$5.1M Sell
45,588
-1,936
-4% -$234K 1.7% 9
2021
Q3 		$5.97M Sell
47,524
-84
-0.2% -$10.8K 2.21% 7
2021
Q2 		$6.45M Buy
47,608
+506
+1% +$66.5K 2.38% 6
2021
Q1 		$6.39M Buy
47,102
+2,056
+5% +$308K 2.61% 6
2020
Q4 		$6.34M Buy
45,046
+6,095
+16% +$781K 2.68% 7
2020
Q3 		$4.34M Buy
38,951
+10,090
+35% +$1.13M 2.07% 9
2020
Q2 		$3.23M Buy
28,861
+450
+2% +$44.3K 1.65% 13
2020
Q1 		$2.2M Sell
28,411
-4,558
-14% -$404K 1.39% 19
2019
Q4 		$3.14M Sell
32,969
-2,369
-7% -$205K 1.45% 19
2019
Q3 		$2.69M Sell
35,338
-1,190
-3% -$98.9K 1.32% 22
2019
Q2 		$3.2M Buy
36,528
+810
+2% +$69.1K 1.66% 17
2019
Q1 		$3.23M Buy
35,718
+6,475
+22% +$551K 1.72% 15
2018
Q4 		$2.1M Sell
29,243
-5,550
-16% -$447K 1.28% 28
2018
Q3 		$3.34M Buy
34,793
+5,393
+18% +$523K 1.65% 17
2018
Q2 		$2.8M Buy
29,400
+5,335
+22% +$490K 1.5% 21
2018
Q1 		$2.11M Buy
24,065
+7,295
+44% +$666K 1.14% 31
2017
Q4 		$1.42M Buy
16,770
+6,775
+68% +$568K 0.72% 41
2017
Q3 		$865K Buy
9,995
+2,770
+38% +$222K 0.46% 53
2017
Q2 		$558K Buy
7,225
+4,590
+174% +$326K 0.31% 72
2017
Q1 		$183K Buy
+2,635
New +$177K 0.1% 124

Other funds holding XBI

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Winfield Associates's XBI Position: Q1 2022 in Review

Winfield Associates reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 73% in Q1 2022, selling an estimated $3.09M and leaving 12,117 shares worth $1.09M. The position accounts for 0.39% of the portfolio, ranked #63.

Winfield Associates first reported a position in XBI in Q1 2017 and has held it in 21 quarters since. The position peaked at $6.45M in Q2 2021. 703 funds tracked by Wall St. Rank hold XBI as of Q1 2022.

  • Winfield Associates held 12,117 shares of State Street SPDR S&P Biotech ETF worth $1.09M as of Q1 2022.
  • Winfield Associates sold 33,471 State Street SPDR S&P Biotech ETF shares in Q1 2022, an estimated $3.09M.
  • State Street SPDR S&P Biotech ETF made up 0.39% of Winfield Associates's portfolio in Q1 2022, its #63 holding.
  • Winfield Associates first reported a position in State Street SPDR S&P Biotech ETF in Q1 2017 and has held it in 21 quarters since.
  • Winfield Associates's State Street SPDR S&P Biotech ETF position peaked at $6.45M in Q2 2021.
  • 703 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.

Based on Winfield Associates's 13F filing for Q1 2022, filed 5 Apr 2022.